FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

研究/论文
返回研究图书馆
PubMedReview

A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors.

Tucker Thomas J, Embrey Mark W, Alleyne Candice, Amin Rupesh P, Bass Alan, Bhatt Bhavana, Bianchi Elisabetta, Branca Danila, Bueters Tjerk, Buist Nicole
Journal of medicinal chemistry2021DOI: 10.1021/acs.jmedchem.1c01599
PCSK9 inhibitorstricyclic peptidesoral bioavailability

质量评分

6/10

引用次数

0

主题

非人类

Peptide Contacts分析

Study Design

Review papers serve a critical role in synthesizing disparate findings into a coherent narrative. For rapidly evolving fields like peptide therapeutics, reviews help researchers and practitioners identify consensus and controversy.

Our Assessment

Quality Assessment: 6/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

These findings advance our understanding of PCSK9 inhibitors, tricyclic peptides, oral bioavailability in meaningful ways.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: A solid contribution to PCSK9 inhibitors, tricyclic peptides, oral bioavailability research. Worth reading alongside other studies on the same compounds for a balanced picture.

关键发现

The paper reviews the development of novel, highly potent tricyclic peptide PCSK9 inhibitors that are orally bioavailable and discusses their potential as next-generation therapeutics for hypercholesterolemia and coronary artery disease.

局限性

As a review article, it does not present new experimental data but rather synthesizes existing knowledge. The focus is on preclinical development stages, lacking clinical trial outcomes.

如何解读这项研究

1

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

2

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

3

Reviews are only as good as the studies they include. Check whether the review examined study quality or simply tallied results.

4

Look for discussion of publication bias — studies with negative results are less likely to be published, which can skew review conclusions.

5

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Peptide Contacts分析

Highlighting the innovative approach and potential clinical impact of novel tricyclic peptide inhibitors targeting PCSK9 in treating hypercholesterolemia and coronary artery disease.

PCSK9 inhibitorstricyclic peptidesoral bioavailability

Novel Tricyclic Peptides: A New Chapter in PCSK9 Inhibition for Heart Health

Published: May 17, 2026 | Source: Journal of medicinal chemistry (2021) | Category: PCSK9 inhibitors, tricyclic peptides, oral bioavailability

Overview

Researchers have developed a series of novel tricyclic peptide inhibitors targeting PCSK9, which could offer significant advancements in the treatment of hypercholesterolemia and coronary artery disease. These new compounds are highly potent and can be taken orally, marking a promising step forward in peptide therapy.

Study Background

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein that regulates cholesterol levels by controlling the number of LDL receptors on liver cells. High levels of PCSK9 reduce the body's ability to clear low-density lipoprotein (LDL), commonly known as "bad" cholesterol, leading to an increased risk of heart disease. Previous research has shown that inhibiting PCSK9 can lower LDL cholesterol and improve cardiovascular outcomes. However, existing inhibitors often require injection or have limited oral bioavailability.

What the Research Found

The study reviewed by Tucker et al. focuses on a series of novel tricyclic peptide inhibitors designed to target PCSK9 more effectively than previous generations of drugs. These new peptides are highly potent and demonstrate excellent oral bioavailability, which is crucial for patient compliance and ease of use. The research highlights the structural modifications made to enhance potency and stability in vivo.

What This Means for Peptide Users

The development of these novel tricyclic peptide inhibitors could lead to more effective treatments for hypercholesterolemia and coronary artery disease that are easier for patients to manage. Oral administration is a significant advantage over existing injectable therapies, potentially increasing patient adherence and improving long-term outcomes.

Limitations and Caveats

As this paper is a review rather than presenting new experimental data, the findings rely heavily on preclinical studies. The lack of clinical trial outcomes means that the true efficacy and safety profiles in human patients remain to be determined. Additionally, while promising, these peptides must undergo rigorous testing before they can be considered for widespread use.

How This Compares to Previous Research

Previous research has established PCSK9 inhibitors as a valuable therapeutic option but highlighted challenges such as limited oral bioavailability and the need for frequent injections. The novel tricyclic peptide inhibitors discussed in this review address these issues, offering a potential breakthrough that could significantly enhance patient care.

Our Analysis

PeptideVault views this study positively due to its innovative approach and promising findings regarding the development of next-generation PCSK9 inhibitors. However, it is crucial to acknowledge that further clinical validation is necessary before definitive conclusions can be drawn about their efficacy and safety in humans.

Key Takeaways

  • The novel tricyclic peptide inhibitors represent a significant advancement in PCSK9 inhibition with high potency and oral bioavailability.
  • These peptides could improve patient compliance by offering an alternative to injectable therapies for managing hypercholesterolemia and coronary artery disease.
  • Further clinical trials are needed to confirm the safety and efficacy of these new compounds.

Original Source

Citation: Tucker Thomas J, Embrey Mark W, Alleyne Candice et al. (2021). A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors.. Journal of medicinal chemistry. DOI: 10.1021/acs.jmedchem.1c01599

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

编辑注释

此分析由Peptide Contacts研究团队撰写,旨在使复杂的发现对肽类社区易于理解。鼓励读者查阅源论文以获取完整的方法和数据。 欲了解PCSK9 inhibitors更多信息,请参阅我们的 研究指南.

引用

Tucker Thomas J, Embrey Mark W, Alleyne Candice et al.. (2021). A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors.. Journal of medicinal chemistry. https://doi.org/10.1021/acs.jmedchem.1c01599

在PubMed查看全文

相关论文

进一步探索

此内容基于同行评审研究仅用于教育目的。不构成医疗建议。在使用任何肽类疗法前,请咨询合格的医疗服务提供者。